New Zealand is an ideal place to start a company to develop kidney organ grafts. NZeno’s business would include the genetic modification of pig cells, testing gene edited cells, cloning and breeding of gene edited pigs, and testing and selecting pigs for compatibility with humans. NZeno would conduct human clinical studies in New Zealand and expects rapid transition to a clinical service in New Zealand following successful surgical studies. The company would then transition the technology to a worldwide market through an IPO to expand its activities or by licensing its technology.
From Auckland, NZeno operates our office and laboratory that has an Export Approved Premises licence from the New Zealand Ministry of Primary Industries. The Designated Pathogen Free pig facility in Invercargill is also has an Export Approved Premises licence.
Europe: NZeno also has our Auckland Island derived pigs and gene-edited pigs in Munich, Germany as part of technology collaboration with partners at the Ludwig Maximillian Institut. The xenotransplant commercialisation offshoot of LMU, XTransplant GmbH, has licensed rights to developing gene-edited pig kidneys and hearts in the European Union using NZeno pigs.
China: In collaboration with the Guangzhou Institute for Biomedicine and Health, NZeno has established cloned NZeno pigs in China and will soon commence studies of gene-edited pig kidneys in non-human primates, prior to conducting the first-in-human trials in New Zealand. Activities in China is co-ordinated by NZeno Biotech Hong Kong.